Carnegie acted as exclusive defence adviser to Exiqon A/S and its owners in the public tender offer from QIAGEN N.V. QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Together with Exiqon, QIAGEN expects to deliver a broad and industry-leading offering of molecular biology solutions – spanning sample technologies, assay technologies, and bioinformatics.
Exiqon is a market leading niche player within RNA analysis. It develops, manufactures and markets reagents and kits to test the actual contents on a molecular level of biological samples (e.g. urine, blood, etc.). The reagents and kits are used by academia and in the pharmaceutical industry in biological research and development of novel medicines and molecular diagnostic tests.